The FDA’s approval of over-the-counter continuous glucose monitoring for children signals a major turning point in diabetes care, with market leaders Dexcom and Abbott expanding consumer access and boosting growth prospects in 2026. The blood glucose monitoring market is being…
The expanding market for continuous glucose monitors is heralding growth, but recent FDA actions against major players highlight trust and software risks that could shape the future of diabetes management technology. A bullish forecast for blood glucose monitoring systems is…
Industry forecasts predict strong growth in blood glucose monitoring over the next decade, driven by rising diabetes prevalence and technological advances in continuous and connected systems, though cost and access remain barriers to wider adoption. Market researchers are increasingly aligned…
Despite differing estimates, analysts agree that the expanding demand for HbA1c testing, driven by rising diabetes prevalence and technological advances, will sustain double-digit growth in the market, with laboratories maintaining their dominance even as decentralised testing gains momentum. Forecasts for…
A groundbreaking study indicates that type 1 diabetes may not be a single disease but two genetically and biologically distinct conditions, potentially transforming diagnosis and treatment approaches. Type 1 diabetes may need to be understood not as a single disorder…
Experts emphasise gradual improvements through quality carbohydrates, regular exercise, and personalised targets, challenging the efficacy of extreme diets to lower HbA1c levels in type 2 diabetes or prediabetes. People with a raised HbA1c reading are unlikely to improve it by…
Current clinical guidance emphasises balanced routines, mindful portion control, and gradual weight loss over extreme dieting to manage prediabetes and lower HbA1c levels effectively and sustainably. For people trying to bring down glycated haemoglobin, or HbA1c, the clearest message from…
India’s growing GLP-1 medication sector is experiencing a seismic shift as affordable generics challenge premium brands like Mounjaro and Ozempic, transforming the landscape of diabetes and obesity treatments. India’s drug market has entered a new phase in which GLP-1 medicines,…
A new review highlights metformin’s promising biological effects on cellular pathways linked to aging, but stops short of recommending it as an anti-ageing pill pending further large-scale trials. Researchers stress its potential to transform healthy lifespan extension if validated in…
The US FDA has authorised Eli Lilly’s Mounjaro to be marketed for reducing major cardiovascular events in adults with type 2 diabetes at elevated risk, marking a significant milestone in incretin medicine approvals and cardiometabolic treatment strategies. US regulators have…
